Back to Search Start Over

Hemodialysis therapy in the United States: what is the dose and does it matter?

Hemodialysis therapy in the United States: what is the dose and does it matter?

Authors :
Friedrich K. Port
Philip J. Held
David W. Liska
Marc N. Turenne
Caitlin E. Carroll
Source :
American journal of kidney diseases : the official journal of the National Kidney Foundation. 24(6)
Publication Year :
1994

Abstract

There is an ongoing discussion in the renal community about how to monitor the treatment of hemodialysis patients in the United States. Comparison of the US patient experience to that of other countries with populations of similar heath status is one way to assess treatment. Another technique involves examining the level of dialysis therapy US patients receive. This paper reviews recent studies which found that the United States has higher mortality than both Japan and Europe and provides additional information as to why those comparisons might be underestimating the mortality differences. We also examine the data on the level of dialysis US patients receive, both as a prescription and as delivered care. We conclude that US patients receive less hemodialysis therapy than their European and Japanese counterparts, and that in general US patients are not receiving the level of dialysis they were prescribed. These factors are correlated with an increased mortality among US hemodialysis patients.

Details

ISSN :
02726386
Volume :
24
Issue :
6
Database :
OpenAIRE
Journal :
American journal of kidney diseases : the official journal of the National Kidney Foundation
Accession number :
edsair.doi.dedup.....df73b877cf34be22e08cdc7476544bc2